EMA Collaboration Task Force
Mission: Closely collaborate with the European Medicine Agency (EMA) to inform them about the progress of in silico methods and learn about EMA requirements to accept digital evidence
The European Medicines Agency (EMA) plays a crucial role in supporting innovation and advancing the development of medicines within the European Union (EU) and its involvement with in silico technologies. This aligns perfectly with the Avicenna Alliance aims to ensure that in silico evidence becomes an integral part of regulatory practice, benefiting patients and fostering healthcare breakthroughs.
The Avicenna Alliance collaborates with the EMA, along with other stakeholders, to advance in silico methods and together they engage with European authorities to promote the role of in silico techniques.
In summary, the EMA Task Force actively collaborates with stakeholders to advance innovative approaches, including in silico technologies, to enhance the safety and efficacy of medicines in the EU.
Goals
- Publish a white paper about the use of in silico methods to provide digital evidences for pharmaceutical applications.
- Informal small-scale closed meetings every 2 months to have fast communication on most interesting topics to work on.
- Public Triple Helix expertise exchange workshops between EMA, industry & academia: first edition on drug-device interaction in Q2, follow up in Q3.
